TY - JOUR
T1 - 1,25-Dihydroxyvitamin D3 induces biphasic NF-κB responses during HL-60 leukemia cells differentiation through protein induction and PI3K/Akt-dependent phosphorylation/degradation of IκB
AU - Tse, Anfernee Kai-Wing
AU - Wan, Chi-Keung
AU - Shen, Xiao-Ling
AU - Zhu, Guo-Yuan
AU - Cheung, Hon-Yeung
AU - Yang, Mengsu
AU - Fong, Wang-Fun
PY - 2007/5/1
Y1 - 2007/5/1
N2 - 1,25-Dihydroxyvitamin D3 (VD3) induces differentiation in a number of leukemia cell lines and under various conditions is able to either stimulate or inhibit nuclear factor kappa B (NF-κB) activity. Here we report a time-dependent biphasic regulation of NF-κB in VD3-treated HL-60 leukemia cells. After VD3 treatment there was an early ∼ 4 h suppression and a late 8-72 h prolonged reactivation of NF-κB. The reactivation of NF-κB was concomitant with increased IKK activities, IKK-mediated IκBα phosphorylation, p65 phosphorylation at residues S276 and S536, p65 nuclear translocation and p65 recruitment to the NF-κB/vitamin D responsive element promoters. In parallel with NF-κB stimulation, there was an up-regulation of NF-κB controlled inflammatory and anti-apoptotic genes such as TNFα, IL-1β and Bcl-xL. VD3-triggered reactivation of NF-κB was associated with PI3K/Akt phosphorylation. PI3K/Akt antagonists suppressed VD3-stimulated IκBα phosphorylation as well as NF-κB-controlled gene expression. The early ∼ 4 h VD3-mediated NF-κB suppression coincided with a prolonged increase of IκBα protein which require de novo protein synthesis, lasted for as least 72 h and was insensitive to MAPK, IKK or PI3K/Akt inhibitors. Our data suggest a novel biphasic regulation of NF-κB in VD3-treated leukemia cells and our results may have provided the first molecular explanation for the contradictory observations reported on VD3-mediated immune-regulation. © 2007 Elsevier Inc. All rights reserved.
AB - 1,25-Dihydroxyvitamin D3 (VD3) induces differentiation in a number of leukemia cell lines and under various conditions is able to either stimulate or inhibit nuclear factor kappa B (NF-κB) activity. Here we report a time-dependent biphasic regulation of NF-κB in VD3-treated HL-60 leukemia cells. After VD3 treatment there was an early ∼ 4 h suppression and a late 8-72 h prolonged reactivation of NF-κB. The reactivation of NF-κB was concomitant with increased IKK activities, IKK-mediated IκBα phosphorylation, p65 phosphorylation at residues S276 and S536, p65 nuclear translocation and p65 recruitment to the NF-κB/vitamin D responsive element promoters. In parallel with NF-κB stimulation, there was an up-regulation of NF-κB controlled inflammatory and anti-apoptotic genes such as TNFα, IL-1β and Bcl-xL. VD3-triggered reactivation of NF-κB was associated with PI3K/Akt phosphorylation. PI3K/Akt antagonists suppressed VD3-stimulated IκBα phosphorylation as well as NF-κB-controlled gene expression. The early ∼ 4 h VD3-mediated NF-κB suppression coincided with a prolonged increase of IκBα protein which require de novo protein synthesis, lasted for as least 72 h and was insensitive to MAPK, IKK or PI3K/Akt inhibitors. Our data suggest a novel biphasic regulation of NF-κB in VD3-treated leukemia cells and our results may have provided the first molecular explanation for the contradictory observations reported on VD3-mediated immune-regulation. © 2007 Elsevier Inc. All rights reserved.
KW - 1,25-Dihydroxyvitamin D3
KW - IKK
KW - Leukemia
KW - Monocytic differentiation
KW - NF-κB
UR - http://www.scopus.com/inward/record.url?scp=34247111909&partnerID=8YFLogxK
UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-34247111909&origin=recordpage
U2 - 10.1016/j.yexcr.2007.02.022
DO - 10.1016/j.yexcr.2007.02.022
M3 - RGC 21 - Publication in refereed journal
C2 - 17397830
SN - 0014-4827
VL - 313
SP - 1722
EP - 1734
JO - Experimental Cell Research
JF - Experimental Cell Research
IS - 8
ER -